Management of Common Toxicities in Metastatic NSCLC Related to Anti-Lung Cancer Therapies with EGFR–TKIs

Rafael Rosell, Enric Carcereny, Radj Gervais, Alain Vergnenegre, Bartomeu Massuti, Enriqueta Felip, Ramon Palmero, Ramon Garcia-Gomez, Cinta Pallares, Jose Miguel Sanchez, Rut Porta, Manuel Cobo, Pilar Garrido, Flavia Longo, Teresa Moran, Amelia Insa, Filippo De Marinis, Romain Corre, Isabel Bover, Alfonso Illiano, Eric Dansin, Javier De Castro, Michele Milella, Noemi Reguart, Giuseppe Altavilla, Ulpiano Jimenez, Mariano Provencio, Miguel Angel Moreno, Josefa Terrasa, Jose Muñoz-Langa, Javier Valdivia, Dolores Isla, Manuel Domine, Olivier Molinier, Julien Mazieres, Nathalie Baize, Rosario Garcia-Campelo, Gilles Robinet, Delvys Rodriguez-Abreu, Guillermo Lopez-Vivanco, Vittorio Gebbia, Lioba Ferrera-Delgado, Pierre Bombaron, Reyes Bernabe, Alessandra Bearz, Angel Artal, Enrico Cortesi, Christian Rolfo, Maria Sanchez-Ronco, Ana Drozdowskyj, Cristina Queralt, Itziar de Aguirre, Jose Luis Ramirez, Jose Javier Sanchez, Miguel Angel Molina, Miquel Taron, Luis Paz-Ares, None, Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncology. ,vol. 13, pp. 239- 246 ,(2012) , 10.1016/S1470-2045(11)70393-X

James Chih-Hsin Yang, Vera Hirsh, Martin Schuler, Nobuyuki Yamamoto, Kenneth J. O'Byrne, Tony S.K. Mok, Victoria Zazulina, Mehdi Shahidi, Juliane Lungershausen, Dan Massey, Michael Palmer, Lecia V. Sequist, Symptom Control and Quality of Life in LUX-Lung 3: A Phase III Study of Afatinib or Cisplatin/Pemetrexed in Patients With Advanced Lung Adenocarcinoma With EGFR Mutations Journal of Clinical Oncology. ,vol. 31, pp. 3342- 3350 ,(2013) , 10.1200/JCO.2012.46.1764

Mario E Lacouture, Milan J Anadkat, René-Jean Bensadoun, Jane Bryce, Alexandre Chan, Joel B Epstein, Beth Eaby-Sandy, Barbara A Murphy, MASCC Skin Toxicity Study Group, None, Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities Supportive Care in Cancer. ,vol. 19, pp. 1079- 1095 ,(2011) , 10.1007/S00520-011-1197-6

Tony S. Mok, Yi-Long Wu, Sumitra Thongprasert, Chih-Hsin Yang, Da-Tong Chu, Nagahiro Saijo, Patrapim Sunpaweravong, Baohui Han, Benjamin Margono, Yukito Ichinose, Yutaka Nishiwaki, Yuichiro Ohe, Jin-Ji Yang, Busyamas Chewaskulyong, Haiyi Jiang, Emma L. Duffield, Claire L. Watkins, Alison A. Armour, Masahiro Fukuoka, Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma The New England Journal of Medicine. ,vol. 361, pp. 947- 957 ,(2009) , 10.1056/NEJMOA0810699

JA Maroun, LB Anthony, N Blais, R Burkes, SD Dowden, G Dranitsaris, B Samson, A Shah, MP Thirlwell, MD Vincent, R Wong, Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on Chemotherapy-Induced Diarrhea. Current Oncology. ,vol. 14, pp. 13- 20 ,(2007) , 10.3747/CO.2007.96

Yi-Long Wu, Caicun Zhou, Cheng-Ping Hu, Jifeng Feng, Shun Lu, Yunchao Huang, Wei Li, Mei Hou, Jian Hua Shi, Kye Young Lee, Chong-Rui Xu, Dan Massey, Miyoung Kim, Yang Shi, Sarayut L Geater, Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial The Lancet Oncology. ,vol. 15, pp. 213- 222 ,(2014) , 10.1016/S1470-2045(13)70604-1

Carlton G. Brown, Linda H. Yoder, Stomatitis: an overview: protecting the oral cavity during cancer treatment. American Journal of Nursing. ,vol. 102, pp. 20- 23 ,(2002) , 10.1097/00000446-200204001-00005

B L Melosky, M E Lacouture, Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: a dermatology-oncology perspective. Skin therapy letter. ,vol. 12, pp. 1- 5 ,(2007)

Leonard B Saltz, Understanding and managing chemotherapy-induced diarrhea. The journal of supportive oncology. ,vol. 1, pp. 35- ,(2003)

B. Melosky, Supportive care treatments for toxicities of anti-egfr and other targeted agents. Current Oncology. ,vol. 19, pp. 59- 63 ,(2012) , 10.3747/CO.19.1054